The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- Valuing and accessing medicines
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- Health Data
Valuing and accessing medicines
Ensuring value, access and uptake of innovative medicines and vaccines, now and in the future
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
Improving the UK's attractiveness for industry, research, development and manufacturing
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
Building better partnerships between industry and NHS and across the Life Sciences sector
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
Building a stronger industry reputation in the UK
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
Providing international leadership and driving global policy
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
Health Data
Improving the UK's health data capability and industry's access to data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
Transforming lives, raising productivity
A new report from PwC for the Association of the British Pharmaceutical Industry reveals a picture of variable and slow access to the newest, innovative treatments.
Read the report from PwC on the value of medicinesLatest news
ABPI response to meeting between industry and Government on HRT supply
The ABPI welcomed today’s meeting between industry and Government on HRT supply.
ABPI welcomes appointment of Madelaine McTernan as Head of HRT Taskforce
It's important that women who need HRT can get the medicines they need
Novo Nordisk’s Pinder Sahota appointed President of the ABPI
Pinder will lead on overseeing the ABPI, the ABPI Board, and the ABPI’s Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA).
ABPI response to guidance on the value of new antibiotics
The ABPI has welcomed the NICE's leadership in introducing a new approach to the evaluation of antibiotics.
Latest blogs and events
Worth the wait – The Goldacre review
Our thoughts on Professor Ben Goldacre’s “Better, broader, safer” report into health data.
Innovative medicines can bring hope to people with rare diseases – let’s get them to patients
England’s Action Plan for Rare Diseases contains important commitments to ensure that people with rare diseases get faster diagnosis, better care and timelier access to the treatments they desperately need.
By working together we can improve the lives of people with rare diseases
Many people are surprised to learn that rare diseases are actually comparatively common. A rare disease is defined as one that affects fewer than one in 2,000 people and it is reckoned that 300 million people worldwide have one. More than 6,000 rare diseases have been identified and about 72% of those have a genetic origin.
Online Workshop on SMC: How to prepare and submit to SMC | 13-14 June 2022
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
Key content hubs
The COP26 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
Coronavirus (COVID-19) was officially declared a pandemic by the World Health Organization on 12 March 2020. As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to this outbreak.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
Antibiotics are crucial for treating pneumonia. But they're under threat from drug resistance. With @asthmalunguk, we're raising awareness to ensure new antibiotics take flight. Find out more: https://t.co/RPyi6UAPv4 #TogetherForAntibiotics pic.twitter.com/KKomnw3BeE
— ABPI (@ABPI_UK) May 27, 2022
For every 1 job in pharmaceutical manufacturing, 3 are supported elsewhere in Northern Ireland's economy. Find out more in our latest report by @Strath_FAI https://t.co/FNJqd5xLHu pic.twitter.com/Mc7SnV0k06
— ABPI (@ABPI_UK) May 24, 2022
Antibiotics are one of the most powerful tools in healthcare. Without new antibiotics, drug resistance could affect the recovery of transplant patients after surgery. Find out more: https://t.co/RPyi6UAPv4 #TogetherForAntibiotics @Kidney_Research pic.twitter.com/Oxb1vSoxGQ
— ABPI (@ABPI_UK) May 24, 2022
1⃣ For better #globalhealth security and disease surveillance, timely and unrestricted access to #pathogens and their genetic information is essential.#C19LessonsLearned #ShareDataOnPathogens
— IFPMA (@IFPMA) May 24, 2022
➡️https://t.co/dfikQbC4nc pic.twitter.com/MY75lg70jL
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/n5lbxuf1/figures-turnover-36-7bn.jpg)
![R and D Investment [2]](/media/4dufmenf/figures-r-d-investment-4-8bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.